How Much Weight Do People Lose on Wegovy?

Last reviewed: June 22, 2026

Last updated: June 22, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Wegovy, the brand-name injectable semaglutide approved by the FDA for chronic weight management, has generated widespread interest due to documented results in controlled studies. Research published in peer-reviewed journals indicates that people using semaglutide achieve meaningful weight reduction when combined with diet and exercise changes. Understanding what typical outcomes look like—and what factors influence individual success—helps set realistic expectations for this therapy.

Average Weight Loss Outcomes on Semaglutide Therapy

The pivotal STEP trials, which evaluated semaglutide's safety and effectiveness, followed patients over 68 weeks and found that those receiving the medication lost approximately 15% of their starting body weight on average. Patients in the control group, who received a placebo, lost about 2.4% of body weight. This 12-point difference highlights the medication's clinical impact when used as directed.

Weight loss typically follows a gradual pattern rather than happening all at once. Most participants experience noticeable reduction within the first 4 to 8 weeks, with continued loss through months 3 and 4 as their dose reaches the therapeutic range. The trajectory depends on individual metabolism, adherence to the treatment plan, dietary choices, and physical activity level.

The PlexusDx Precision Peptide Genetic Test analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to Wegovy or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

Timeline for Seeing Weight Loss Results

Most people begin noticing appetite suppression and early weight reduction within the first 2 to 3 weeks of starting semaglutide therapy. This early signal comes from the medication's action on GLP-1 receptors in the brain, which regulate hunger and satiety. However, measurable weight loss on a scale typically appears between weeks 4 and 8.

The dose-escalation phase, which often spans 4 to 6 months, creates a gradual timeline for reaching maximum therapeutic benefit. Starting at a low dose and increasing every 4 weeks allows the body to adjust and helps minimize side effects. During this ramp-up period, weight loss continues steadily but may not accelerate dramatically until the patient reaches their optimal maintenance dose.

Sustained weight loss continues for at least 12 months in clinical trials, with many patients maintaining results through ongoing treatment. Stopping the medication without lifestyle changes typically leads to weight regain within months, underscoring the importance of combining pharmacotherapy with behavioral modifications.

Factors That Influence Individual Weight Loss Success

Genetic predisposition plays a significant role in how much weight someone loses on semaglutide. Variants in the GIPR gene affect GLP-1 secretion and nutrient sensing, while FTO variants influence appetite regulation and energy expenditure. MC4R gene differences alter satiety signals variants modify receptor sensitivity to the medication itself. These genetic factors do not determine outcomes alone but substantially shape the starting point and ceiling of response.

Dietary adherence and physical activity are equally critical determinants of weight loss magnitude. Patients who reduce caloric intake below their baseline expenditure lose more weight than those who simply rely on appetite suppression without intentional behavior change. Adding 150 minutes of moderate-intensity exercise per week amplifies results beyond medication effects alone.

Baseline metabolic health, age, and presence of diabetes also influence outcomes. Patients with type 2 diabetes often see comparable or slightly larger percentage weight loss. Older adults may experience slower metabolism shifts but still benefit substantially from semaglutide's dual effects on appetite and glucose control. Sleep quality, stress management, and medication adherence further modulate the response trajectory.

PlexusDx Semaglutide Injections and Personalized Therapy Options

PlexusDx supplies compounded semaglutide injections from licensed 503A compounding pharmacies, at $189/mo month-to-month, or from $149/mo on the 6-month plan across all commitment tiers. Unlike some pricing models, PlexusDx holds the monthly cost flat even as dose increases—a principle reflected in the company's philosophy that 'your dose may need to go up, your price won't.' This approach removes cost barriers to reaching optimal therapeutic dosing.

The PlexusDx Precision Peptide Genetic Test ($298) analyzes GIPR, FTO, and MC4R — variants that relate to GLP-1 and related signaling pathways. It does not predict your response to tirzepatide or determine your dose; it offers pathway-level context for a conversation with your provider. Genetics is a guide, not a guarantee.

PlexusDx serves all 50 states without requiring insurance, membership fees, or prior authorization from insurers. Treatments are HSA and FSA eligible, making them accessible to a broad patient population. Online consultations with licensed practitioners mean patients can begin therapy without lengthy office visits, while receiving the same clinical rigor as in-person care.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

How much weight do most people lose on Wegovy or semaglutide in the first month?

Initial weight loss in month one typically ranges from 2 to 4 pounds as the medication begins suppressing appetite and the dose is still ramping up. Larger losses often appear in months 2 through 4 once the therapeutic dose is reached. Individual variation is normal, and genetics play a role in early response speed.

Is 15% weight loss typical for everyone on semaglutide?

No — the Precision Peptide Genetic Test does not predict your response to Wegovy or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Can I get semaglutide from PlexusDx if I don't have insurance?

Yes. PlexusDx compounded semaglutide injections are $189/mo month-to-month, or from $149/mo on the 6-month plan and require no insurance, membership, or prior authorization. Treatment is available in all 50 states and is eligible for HSA and FSA accounts, making it accessible regardless of insurance status.

What happens to weight loss if I stop taking semaglutide?

Clinical evidence indicates that most weight regain occurs within 12 months after stopping semaglutide if diet and exercise patterns revert to baseline. Maintaining lifestyle changes—reduced calorie intake and regular physical activity—can slow or minimize regain. This underscores the need for ongoing therapy combined with sustainable behavioral modification.

How can the PlexusDx genetic test improve my weight loss results?

No — the Precision Peptide Genetic Test does not predict your response to tirzepatide or any specific medication. It analyzes pathway-level variants (GIPR, FTO, and MC4R) that relate to the biology involved, offering context for a conversation with your provider rather than a prediction.

Related Reading

• Wegovy For Losing Weight
• Wegovy For Weight Loss 2
• Wegovy Weight Loss Pills
• Wegovy Vs Zepbound Weight Loss

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.